<DOC>
	<DOCNO>NCT02406833</DOCNO>
	<brief_summary>This study evaluate addition ISTH0036 , antisense oligonucleotide TGF-β2 , glaucoma filtration surgery ( trabeculectomy ) . The treatment aim improve surgery outcome prevention excessive scar trabecular meshwork transformation .</brief_summary>
	<brief_title>Phase I Dose Escalation Study Investigate Safety ISTH0036 Subjects With Glaucoma Undergoing Trabeculectomy</brief_title>
	<detailed_description>The transform growth factor beta ( TGF-β ) know play key role glaucoma . Increased level TGF-β2 eye link trabecular meshwork transformation , increase intraocular pressure direct optic nerve damage . Trabeculectomy standard surgical intervention reduce intraocular pressure subject longer sufficiently respond pressure-lowering medication . Scarring surgically open canal ( bleb ) often abolish effect trabeculectomy ( despite intraoperative use Mitomycin C prevent ) . TGF-β2 described play distinct role fibrotic process bleb closure .</detailed_description>
	<mesh_term>Glaucoma</mesh_term>
	<mesh_term>Glaucoma , Open-Angle</mesh_term>
	<criteria>Subject schedule trabeculectomy Mitomycin C Subject longer tolerate benefit pharmacologic treatment glaucoma History relevant ocular trauma &lt; 6 month ocular infection/inflammation &lt; 3 month severe central visual field loss within 6 month unrelated glaucoma pregnant nursing woman subject use adequate contraception history evidence clinically significant disorder , condition disease would pose risk subject safety interfere study evaluation , procedure interpretation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>glaucoma</keyword>
	<keyword>trabeculectomy</keyword>
</DOC>